Search clinical trials for: Ad26.ZEBOV vaccine

Total 6240 results

Universiteit Antwerpen
Johnson & Johnson; University of Kinshasa; Innovative Medicines Initiative; Coalition... and other collaborators

Completed

Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola (EBOVAC3DRC)

Ebola Virus Disease

Congo, The Democratic Republic of the
Crucell Holland BV

Completed

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
London School of Hygiene and Tropical Medicine
Public Health England; Janssen Vaccines & Prevention B.V.; Epicentre; Coalition... and other collaborators

Active, not recruiting

Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

Ebola Virus Disease

Congo, The Democratic Republic of the
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
Janssen Vaccines & Prevention B.V.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

Healthy

United States
MRC/UVRI and LSHTM Uganda Research Unit
Epicentre, Paris, France.; Janssen Pharmaceutica N.V., Belgium; Coalition for... and other collaborators

Completed

ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)

Ebola Virus Disease

Uganda
University of Oxford

Completed

A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV

Ebola Virus Disease

United Kingdom
Janssen Vaccines & Prevention B.V.
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Completed

A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

Ebola Virus Disease

Guinea, Sierra Leone
National Institute of Allergy and Infectious Diseases...
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Active, not recruiting

Partnership for Research on Ebola VACcinations (PREVAC)

Ebola Virus Disease

Guinea, Liberia, Mali, Sierra Leone
Janssen Vaccines & Prevention B.V.

Completed

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Ebola

United States
Janssen Vaccines & Prevention B.V.
Bavarian Nordic GmbH

Terminated

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Hemorrhagic Fever, Ebola

France, United Kingdom, Kenya, United States, Uganda, Burkina Faso, Tanzania
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults

HIV Infections

United States
London School of Hygiene and Tropical Medicine
University of Sierra Leone; Janssen Vaccines & Prevention B.V.

Active, not recruiting

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

Infections | RNA Virus Infections | Virus Diseases | Mononegavirales Infections | Hemorrhagic Fevers, Viral | Hemorrhagic Fever, Ebola | Filoviridae Infections | Physiological Effects of Drugs | Vaccines | Ebola | Immunologic Factors

Sierra Leone
London School of Hygiene and Tropical Medicine

Completed

Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)

Hiv | Ebola Virus Disease | Ebola

Kenya, Uganda
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; University...

Completed

A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

Ebola Viral Disease

France, United Kingdom
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; Centre Muraz and other collaborators

Completed

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Hemorrhagic Fever, Ebola

Kenya, Uganda, Burkina Faso, Côte D'Ivoire
Janssen Vaccines & Prevention B.V.
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Hemorrhagic Fever, Ebola

United States, Uganda, Kenya, Mozambique, Nigeria, Tanzania
Crucell Holland BV

Completed

A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United Kingdom
Janssen Vaccines & Prevention B.V.
Emory University; Coalition for Epidemic Preparedness Innovations; Center for...

Completed

A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women (INGABO)

Healthy

Rwanda
Janssen Vaccines & Prevention B.V.

Completed

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United States
Crucell Holland BV

Completed

A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

Kenya
Crucell Holland BV

Completed

A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

Tanzania, Uganda
Novavax

Completed

Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects

Ebola

Australia
Janssen Vaccines & Prevention B.V.
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Completed

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo (EBOVAC-Salone)

Ebola Virus Disease

Sierra Leone
International AIDS Vaccine Initiative
National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel... and other collaborators

Completed

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

HIV Infections

United States, Kenya, Rwanda, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

Ebola Disease | Marburg Disease

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Influenza, Human Prevention | Respiratory Syncytial Viruses Prevention

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure

Healthy Volunteers

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

Respiratory Syncytial Virus Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

Respiratory Syncytial Virus Prevention

United States
London School of Hygiene and Tropical Medicine
University of Sierra Leone; Innovative Medicines Initiative

Completed

Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)

Ebola Virus Disease

Sierra Leone
Jiangsu Province Centers for Disease Control and...
Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology Inc

Completed

A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization

Ebola Virus Disease

China
Cecile Tremblay
Merck Sharp & Dohme LLC; Dalhousie University; Université de Montréal; Coalition... and other collaborators

Active, not recruiting

African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola

Ebola

Canada
Jiangsu Province Centers for Disease Control and...
Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology Inc

Completed

A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.

Ebola Virus Disease

China
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

Respiratory Syncytial Virus Infection Prevention

Germany, Spain, Belgium, Sweden, United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults

HIV Infections

United States
University Medical Center Groningen
Radboud University Medical Center; Erasmus Medical Center; Academisch Medisch... and other collaborators

Completed

RECOVAC Repeated Vaccination Study

Kidney Diseases | Covid19 | SARS-CoV2 Infection | Vaccine Response Impaired

Netherlands
Janssen Pharmaceutical K.K.

Terminated

A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants

Respiratory Syncytial Virus Prevention

Japan
Hospital Moinhos de Vento
Pfizer; Universidade Federal do Paraná; Inova Medical

Completed

A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil

Covid19

Brazil
University of Oxford

Enrolling by invitation

Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients (CVTB)

Tuberculosis | Covid-19 Pandemics

Thailand
Centre Hospitalier Universitaire de Saint Etienne

Active, not recruiting

Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen (CoviCompare_J)

Healthy Volunteers

France
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

COVID-19 Prevention

United States, Belgium, Poland
International AIDS Vaccine Initiative
Biomedical Advanced Research and Development Authority

Active, not recruiting

Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health

Ebola Sudan Virus Disease

United States
Emory University
Washington University School of Medicine; Merck Sharp & Dohme LLC

Not yet recruiting

Immunology of Ebola Vaccine

Ebola Virus Disease

United States
Massachusetts General Hospital

Completed

Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (MOSAICO)

Healthy

United States, Mexico, Spain, Puerto Rico, Italy, Poland, Argentina, Brazil, Peru
AstraZeneca

Completed

Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study (REFORCO-B)

COVID-19

Brazil
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Wits Health Consortium (Pty) Ltd
Fred Hutchinson Cancer Center; Janssen Vaccines & Prevention B.V.; National Institute... and other collaborators

Completed

Sisonke (Together): OPEN LABEL TRIAL COVID-19 (Sisonke)

SARS (Severe Acute Respiratory Syndrome)

South Africa
Boris Juelg, MD PhD
National Institute of Allergy and Infectious Diseases (NIAID); The University... and other collaborators

Recruiting

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Acquired Immunodeficiency Syndrome | Sexually Transmitted Diseases, Viral | Retroviridae Infections | HIV | Immunologic Deficiency Syndrome, Acquired

United States

Search clinical trials for: Ad26.ZEBOV vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations